FY2025 · ended Dec 31, 2025 · Revenue $0, -100.0% YoY · Filed Mar 25, 2026
Exicure, Inc. (XCUR) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and a net loss of $4.9 million. Free cash flow was -$8.6 million. As of Jun 30, 2026 it held $1.7 million in cash and investments and $0 in total debt.
Revenue (TTM)
$0
Net income (TTM)
$-8.28M
-5.1% vs year-ago TTM
Operating cash flow (TTM)
$-6.70M
-29.6% vs year-ago TTM
Free cash flow (TTM)
$-7.02M
EPS (TTM)
$-1.30
+29.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
6.37M
+0.9% vs prior year
Net cash
$1.72M
as of Jun 30, 2026
Operating margin
-2446.4%
FY 2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- XCUR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Chicago, IL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1698530
- Former names
- Max-1 Acquisition Corp (until Sep 28, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $500,000 | $0 | $28.8M | -$483,000 |
| Operating income | -$4.2M | -$12.2M | -$15.0M | -$1.8M | -$62.5M |
| Net income | -$4.9M | -$9.7M | -$16.9M | -$2.6M | -$64.1M |
| Diluted EPS | -$0.79 | -$4.75 | -$10.55 | -$0.56 | -$21.70 |
| Operating cash flow | -$8.6M | -$2.9M | -$10.4M | -$35.7M | -$34.8M |
| Free cash flow | -$8.6M | — | -$10.4M | -$35.7M | -$35.8M |
| Total assets | $14.0M | $15.1M | $11.6M | $23.3M | $64.9M |
| Total liabilities | $10.1M | $8.3M | $8.5M | $8.4M | $53.6M |
| Stockholders' equity | $3.9M | $6.8M | $3.0M | $14.9M | $11.2M |
| Cash and investments | $3.7M | $12.5M | $2.0M | $9.8M | $48.3M |
| Total debt | $176,000 | $5.9M | $6.7M | $7.3M | $14.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Listing notice
|
Sep 16, 2026 | Sep 16, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 1, 2026 | Jun 1, 2026 |
| 10-Q | Quarterly report | May 29, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Officer or director change
|
Apr 10, 2026 | Apr 8, 2026 |
All 532 Exicure, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.